House Subcommittee Hearing Discusses Impacts of Drug Pricing on Health Care Costs

Why It Matters

The testimony signals strong hospital‑sector resistance to reforms that could increase drug‑price volatility and limit hospital control over pharmacy services, potentially raising costs for patients and insurers alike.

Key Takeaways

• AHA opposes shifting 340B to rebate model
• Calls for policies improving medication and device access
• Requests ban on insurer‑mandated specialty pharmacies
• Highlights drug shortages and supply‑chain disruptions
• Emphasizes patient safety risks from private‑payer rules

Pulse Analysis

The hearing underscores a growing policy clash over the 340B Drug Pricing Program, a federal initiative that allows hospitals serving vulnerable populations to purchase drugs at discounted rates. Critics argue the program inflates overall drug spending, while supporters like the AHA contend that moving to a rebate‑only structure would erode the financial safety net that helps hospitals manage high‑cost therapies. By preserving 340B discounts, hospitals can offset the price gap between wholesale acquisition costs and reimbursed amounts, keeping essential medicines affordable for low‑income patients.

Supply‑chain stability emerged as another focal point, with the AHA warning that recent drug shortages stem from fragmented distribution channels and inconsistent pricing incentives. Disruptions not only delay treatment but also force hospitals to source expensive alternatives, driving up operational costs. The subcommittee’s discussion highlighted the need for coordinated federal action—such as streamlined reporting requirements and incentives for domestic manufacturing—to mitigate bottlenecks and ensure a reliable flow of both generic and specialty drugs.

Finally, the AHA’s objection to private‑payer mandates that route clinician‑administered drugs through insurer‑chosen specialty pharmacies reflects broader concerns about autonomy and patient safety. Hospital pharmacies argue that their integrated clinical expertise reduces medication errors and improves therapeutic outcomes. Limiting this capability could increase administrative overhead and expose patients to fragmented care. As lawmakers weigh these competing interests, the outcome will shape drug‑pricing dynamics, hospital budgeting, and ultimately, the cost burden borne by American consumers.

House subcommittee hearing discusses impacts of drug pricing on health care costs

Feb 11, 2026 · 03:54 PM

The House Energy and Commerce Subcommittee on Health on Feb. 11 hosted a hearing titled “Lowering Health Care Costs for All Americans: An Examination of the Prescription Drug Supply Chain.” The American Hospital Association (AHA) provided a statement for the hearing that shared concerns on issues such as efforts to weaken the 340B Drug Pricing Program, drug shortages and other drug‑supply‑chain disruptions, and private‑payer policies undermining access and patient safety.

The AHA made a series of recommendations to Congress, including:

• Opposing efforts to move 340B pricing to a rebate model.

• Enacting policies to improve medication and device access.

• Prohibiting private‑payer policies that require hospitals to obtain clinician‑administered drugs through insurer‑selected specialty pharmacies rather than through their own hospital pharmacy systems.

Image: AHA comment letter (illustration accompanying the article).